Dapagliflozin 10mg QD + Gliclazide 30mg QD
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2, Diabetic Nephropathies
Trial Timeline
Feb 1, 2016 → Sep 1, 2018
NCT ID
NCT02682563About Dapagliflozin 10mg QD + Gliclazide 30mg QD
Dapagliflozin 10mg QD + Gliclazide 30mg QD is a approved stage product being developed by AstraZeneca for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT02682563. Target conditions include Diabetes Mellitus, Type 2, Diabetic Nephropathies.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02682563 | Approved | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2